In BL-CL breast cancers, the rationale of CHK1 targeted therapy is supported by the documented evidence of alterations in the DNA damage repair machinery through either the high rate of BRCA or p53 mutations [7,8,11]. The gene discussed is TP53; the disease is Burkitt lymphoma.